Loading...
XKRX253840
Market cap101mUSD
Jan 09, Last price  
9,100.00KRW
1D
1.68%
1Q
59.37%
IPO
40.00%
Name

SugenTech Inc

Chart & Performance

D1W1MN
XKRX:253840 chart
P/E
—
P/S
20.83
EPS
—
Div Yield, %
1.67%
Shrs. gr., 5y
17.97%
Rev. gr., 5y
5.53%
Revenues
7.13b
-92.97%
601,109,6181,090,268,1623,439,993,3035,448,790,0673,845,080,64641,351,848,29877,201,041,452101,399,255,8337,132,305,540
Net income
-17.24b
L
-1,511,996,258-1,558,392,021-20,960,485,413-40,915,428,995-9,561,056,493-41,018,413,35936,151,559,44026,716,630,860-17,238,284,500
CFO
-12.15b
L
-1,197,283,537-1,335,399,006-909,594,013-3,134,053,492-4,011,329,34614,332,738,08638,955,129,42730,427,994,726-12,153,244,980
Dividend
Dec 27, 2023150 KRW/sh

Profile

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers Multiplex BLOT disease diagnostic devices, such as immunoblot processor, semi and full automation, and molecular diagnostic systems, as well as test items; and self-testing products, including digital ovulation, pregnancy test, and early sign pregnancy test, as well as mobile testing products. It also provides point of care testing analyzers and test items for testing of M.tuberculosis, M.bovis, SARS-CoV-2 antibodies and antigens, flu A/B antigens, and CRP/hsCRP /dualCRP, as well as for measuring procalcitonin, troponin I, hemoglobinA1c, human chorionic gonadotropin, immunoglobulin E, and influenza A/B. The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.
URL
https://www.sugentech.com/
IPO date
Nov 11, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,132,306
-92.97%
101,399,256
31.34%
Cost of revenue
21,445,501
68,666,802
Unusual Expense (Income)
NOPBT
(14,313,195)
32,732,454
NOPBT Margin
32.28%
Operating Taxes
(1,343,651)
5,644,544
Tax Rate
17.24%
NOPAT
(12,969,544)
27,087,910
Net income
(17,238,284)
-164.52%
26,716,631
-26.10%
Dividends
(2,484,129)
Dividend yield
1.99%
Proceeds from repurchase of equity
(11,593,147)
843,027
BB yield
9.29%
-0.46%
Debt
Debt current
14,674,884
19,418,686
Long-term debt
1,253,829
1,122,899
Deferred revenue
(1)
Other long-term liabilities
1,730,947
3,007,268
Net debt
(68,607,098)
(100,087,245)
Cash flow
Cash from operating activities
(12,153,245)
30,427,995
CAPEX
(5,650,977)
(16,404,362)
Cash from investing activities
1,990,206
(41,967,014)
Cash from financing activities
(19,443,964)
(2,167,450)
FCF
(19,126,927)
9,761,577
Balance
Cash
66,681,251
109,874,003
Long term investments
17,854,560
10,754,827
Excess cash
84,179,195
115,558,867
Stockholders' equity
56,078,147
81,538,637
Invested Capital
73,274,843
76,258,662
ROIC
29.41%
ROCE
20.74%
EV
Common stock shares outstanding
16,101
18,039
Price
7,750.00
-23.65%
10,150.00
-27.50%
Market cap
124,786,385
-31.85%
183,094,277
-21.89%
EV
56,239,301
87,241,840
EBITDA
(9,530,058)
36,349,362
EV/EBITDA
2.40
Interest
1,823,301
2,140,463
Interest/NOPBT
6.54%